Phaseline

Companies › Maze Therapeutics

Maze Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Metabolic and endocrine, Genitourinary; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MZE782–Phase 2Phenylketonuria (PKU)Dec 2027
MZE829
APOL1 kidney disease modulator
–Phase 2Proteinuric Kidney Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06830629MZE829Phase 2Proteinuric Kidney DiseaseGenitourinarySep 2026
NCT07694440MZE782Phase 2Phenylketonuria (PKU)Metabolic and endocrineDec 2027

From the company's SEC filings

Cash and short-term investments of $390m on 2026-09-30; operating cash outflow about $117m a year; runway about 40 months at that burn, to Jan 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Vifor Pharma Sparrow Pharmaceuticals Vogenx Neurocrine Switzerland SAb Biotherapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.